Samer Choucair: Rehabilitation Robots Are Repricing Healthcare and Opening a New Market for Capital
Investment leader Samer Choucair said medical rehabilitation robotics entered a new phase in 2026, moving beyond mechanical systems that simply assist patient movement toward intelligent platforms capable of learning from therapists and adjusting force and resistance in real time.
Choucair said this shift is redefining the economics of physical therapy by increasing treatment intensity, expanding the viability of home-based rehabilitation, and turning therapist shortages into a catalyst for automation investment. Market estimates valued the global rehabilitation robotics sector at roughly $1.5 billion to $2.1 billion in 2025, with expectations that it could grow to several billion dollars in the early 2030s. Meanwhile, the smart rehabilitation exoskeleton market was estimated at around $507 million, with some growth scenarios projecting it could reach approximately $2.7 billion by 2032.
According to Samer Choucair, value is no longer concentrated in the motor, frame, or mechanical hardware itself. The real value increasingly lies in a system’s ability to convert movement data into personalized treatment protocols and measurable clinical outcomes.
Capital Is Following the Data, Not the Hardware
Samer Choucair said institutional investors are increasingly viewing rehabilitation robotics as part of the broader rise of “physical AI” in healthcare rather than simply another medical-device category.
He added that the companies attracting the strongest investor interest are those combining long-term clinical data, regulatory approvals, and distribution agreements with hospitals or insurers.
“The device itself can become a commodity exposed to price competition,” Choucair said. “But a platform that connects the home rehabilitation session to the electronic health record and can predict the patient’s recovery trajectory is an asset that can be repriced through software and subscription revenue.”
Choucair said investment opportunities now span exoskeletons, upper-limb rehabilitation robots, home rehabilitation systems, motion-capture software, remote-care services, and critical manufacturing components including actuators, force sensors, and lightweight materials.
Robotics Is Reshaping Clinic Economics
Samer Choucair said robots are unlikely to eliminate the role of the physical therapist, but they can significantly alter the production model inside rehabilitation clinics.
High-volume repetition can increasingly be handled by machines, while diagnosis, clinical judgment, and adjustments to the treatment plan remain under the supervision of trained professionals.
Choucair said this model could put pressure on smaller clinics that cannot finance the necessary capital investment, while larger hospital networks and rehabilitation-center operators may be able to improve asset utilization and increase the number of patients treated per therapist.
Clinical systems range in price from tens of thousands of dollars for wearable exoskeletons to hundreds of thousands of dollars for advanced gait-rehabilitation systems. Some industry estimates also suggest that approximately 12,000 smart rehabilitation exoskeleton units were produced in 2025, with average prices around $43,000 under certain market assumptions.
Saudi Arabia Can Evolve From Import Market to Innovation Testbed
Samer Choucair said Saudi Arabia has an opportunity to establish an advanced position in the sector, supported by Vision 2030 priorities around healthcare transformation, digitalization, and the localization of medical-device manufacturing.
Announced investment across the broader healthcare-transformation ecosystem has exceeded SAR 133 billion in the context of recent partnerships and industry events, alongside the expansion of the Seha Virtual Hospital model and wider adoption of robotic surgery.
Saudi Aramco’s investment arm, Prosperity7, has also invested in Fourier Intelligence, a company specializing in neurorehabilitation robotics, as the business looks to expand its presence in the Saudi market.
Choucair said the Kingdom’s advantage lies in the combination of institutional purchasing power and the potential to create a domestic manufacturing base. But he warned investors against treating technology procurement itself as the investment thesis.
“A successful institutional investment does not simply ask how many machines were purchased,” Choucair said. “It asks how many hours a day each system is actually used, whether staff are properly trained, and whether the resulting data are connected to the insurance and reimbursement system. Without that loop, technology becomes an underutilized fixed asset.”
The Opportunity Is in the Platform, Not the Machine
Samer Choucair said the most attractive opportunities are likely to emerge in remote rehabilitation, lower-cost exoskeletons, clinical-outcomes software, and the management of robotic fleets across hospitals and rehabilitation networks.
He also expects the sector to see increasing merger and acquisition activity between traditional medical-device manufacturers and software companies as the distinction between hardware and data platforms becomes less important.
At the same time, Choucair warned investors to watch regulatory and safety risks, weak insurance reimbursement, platform fragmentation, and excessive enthusiasm around artificial intelligence before companies have demonstrated meaningful clinical outcomes.
Demographics should remain a structural driver of demand, particularly as populations age and the prevalence of strokes and neurological injuries continues to create long-term rehabilitation needs.
For that reason, Choucair said the long-term investment thesis should not be built around “anything with the word robot attached to it.” Instead, investors should focus on businesses that control valuable clinical data, maintain strong relationships with payers, and possess genuine manufacturing or distribution capabilities.
According to Samer Choucair, the ultimate winner in rehabilitation robotics will not necessarily be the company that builds the most sophisticated machine.
It will be the company that turns the robot into a productivity platform — making every hour of therapy more valuable and every unit of invested capital more productive.